Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules, 40 mg.
At the time of writing on June 28, 2024 at 5:16 pm shares of Alembic Pharmaceuticals were trading at ₹880 which is a 0.11% gain than the previous close. The stock has gained a total of 37% in the last one year, and 14% since the beginning of the year.
The approved ANDA is equivalent to the reference listed drug product (RLD), Oracea Capsules, 40 mg, by Galderma Laboratories, L.P.
Doxycycline capsules are specifically for treating inflammatory lesions (papules and pustules) of rosacea in adult patients. The market size for Doxycycline Capsules, 40 mg is estimated at US$ 123 million for the twelve months ending March 2024, according to IQVIA.
Alembic now has a total of 205 ANDA approvals from the USFDA, comprising 179 final approvals and 26 tentative approvals.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
